WIM
Woodford Investment Management Portfolio holdings
AUM
$310M
This Quarter Return
+7.16%
1 Year Return
-17.41%
3 Year Return
-27.69%
5 Year Return
+67.02%
10 Year Return
–
AUM
$2.18B
AUM Growth
+$2.18B
(-20%)
Cap. Flow
-$777M
Cap. Flow
% of AUM
-35.66%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
7
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
AbbVie
ABBV
|
$709M |
| 2 |
Gilead Sciences
GILD
|
$44.9M |
| 3 |
Alkermes
ALKS
|
$15.9M |
| 4 |
Prothena Corp
PRTA
|
$3.29M |
| 5 |
Biogen
BIIB
|
$2.68M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Prothena Corp
PRTA
$441M
| $735M | 33.74% | 11,349,614 -50,810 | -0.4% | -$3.29M |
|
|
2
Alkermes
ALKS
$4.78B
| $373M | 17.12% | 7,335,683 -312,294 | -4% | -$15.9M |
|
3
Theravance Biopharma
TBPH
$699M
| $367M | 16.83% | 10,706,108 -72 | -0% | -$2.47K |
|
|
4
AbbVie
ABBV
$372B
| $344M | 15.81% | 3,875,358 -7,979,400 | -67% | -$709M |
|
|
5
Gilead Sciences
GILD
$140B
| $135M | 6.19% | 1,665,592 -554,508 | -25% | -$44.9M |
|
|
6
Biogen
BIIB
$19.4B
| $113M | 5.18% | 360,084 -8,561 | -2% | -$2.68M |
|
|
BIVV
7
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $112M | 5.14% | 1,960,325 -17,439 | -0.9% | -$995K |
|